AGENCY: Food and Drug Administration, HHS.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 13 new animal drug applications (NADAs). In a final rule published elsewhere in this issue of the Federal Register, FDA is amending the regulations to remove portions reflecting approval of these NADAs.

DATES: Withdrawal of approval is effective April 11, 2011.

FOR FURTHER INFORMATION CONTACT: John Bartkowiak, Center for Veterinary Medicine (HFV–212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–276–9079, e-mail: john.bartkowiak@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: The sponsors of the 13 approved NADAs listed in table 1 have requested that FDA withdraw approval because the products are no longer manufactured or marketed.

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>NADA No. Product (Established Name of Drug)</th>
<th>21 CFR Section Affected (Sponsor’s Drug Labeler Code)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roche Vitamins, Inc., 45 Waterview Blvd., Parsippany, NJ 07054–1298.</td>
<td>NADA 093–029, UNITOP Cream (cuprimycin)</td>
<td>524.520, 063238</td>
</tr>
<tr>
<td>Quali-Tech Products, Inc., 318 Lake Hazeltine Dr., Chaska, MN 55318.</td>
<td>NADA 097–981, TYLAN 40 Sulfa-G Premix (tylosin phosphate/sulfamethazine)</td>
<td>558.630, 016968</td>
</tr>
<tr>
<td>Abaxis Pharmaceutical Products, Division of Abaxis Bioscience, 6133 River Rd., suite 500, Rosemont, IL 60018.</td>
<td>NADA 100–840, Chorionic Gonadotropin for Injection (chorionic gonadotropin)</td>
<td>522.1081, 063323</td>
</tr>
<tr>
<td>Furst-McNess Co., Freeport, IL 61032</td>
<td>NADA 100–991, McNeil Custom Premix L200 (tylosin phosphate)</td>
<td>558.625, 010439</td>
</tr>
<tr>
<td>Fort Dodge Animal Health, Division of Wyeth Holdings, a wholly owned subsidiary of Pfizer, Inc., 235 East 42nd St., New York, NY 10017.</td>
<td>NADA 101–079, TRAMISOL–10% Pig Wormer (levamisole)</td>
<td>Not codified, 000856</td>
</tr>
<tr>
<td>Waterloo Mills Co., 2050 Mitchell Ave., Waterloo, IA 50704.</td>
<td>NADA 101–905, Mill Co-Medicator TY–10 (tylosin phosphate)</td>
<td>558.625, 017139</td>
</tr>
<tr>
<td>Pegasus Laboratories, Inc., 8809 Ely Rd., Pensacola, FL 32514.</td>
<td>NADA 102–824, Phenylbutazone Tablets (phenylbutazone)</td>
<td>520.1720a, 055246</td>
</tr>
<tr>
<td>Wendt Laboratories, Inc., 100 Nancy Dr., Belle Plaine, MN 56011.</td>
<td>NADA 106–487, DEC Tabs (diethylcarbamazine citrate)</td>
<td>520.622a, 015579</td>
</tr>
<tr>
<td>Wendt Laboratories, Inc., 100 Nancy Dr., Belle Plaine, MN 56011.</td>
<td>NADA 108–863, DEC Chewable Tabs (diethylcarbamazine citrate)</td>
<td>520.622c, 015579</td>
</tr>
<tr>
<td>Furst-McNess Co., Freeport, IL 61032</td>
<td>NADA 140–820, TYLAN 40 Sulfa-G Premix (tylosin phosphate/sulfamethazine)</td>
<td>558.630, 010439</td>
</tr>
<tr>
<td>Furst-McNess Co., Freeport, IL 61032</td>
<td>NADA 140–825, BANMINTH Intermediate Premix (pyrantel tartrate)</td>
<td>558.485, 010439</td>
</tr>
<tr>
<td>Hess &amp; Clark, Inc., 944 Nandino Blvd., Lexington, KY 40511.</td>
<td>NADA 140–910, NFZ Wound Powder (nitrofurazone)</td>
<td>524.1580c, 050749</td>
</tr>
</tbody>
</table>

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 Notice of withdrawal of approval of application (21 CFR 514.116), notice is given that approval of NADAs 93–029, 97–981, 100–840, 100–991, 101–079, 101–905, 101–906, 102–824, 108–487, 108–863, 140–820, 140–825, and 140–910, and all supplements and amendments thereto, is hereby withdrawn, effective April 11, 2011.
In a final rule published elsewhere in this issue of the Federal Register, FDA is amending the animal drug regulations to reflect the withdrawal of approval of these NADAs.

Dated: March 25, 2011.

Leslie Kux,
Acting Assistant Commissioner for Policy.

[FR Doc. 2011–7558 Filed 3–30–11; 8:45 am]
BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Endocrinology and Metabolism.

Date: April 25, 2011.

Time: 11 a.m. to 5:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Krish Krishnan, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6164, MSC 7892, Bethesda, MD 20892, (301) 435–1041, krishnak@csr.nih.gov.

Name of Committee: Biengineering Sciences & Technologies Integrated Review Group; Biomaterials and Biointerfaces Study Section.

Date: April 27–28, 2011.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: InterContinental Chicago Magnificent Mile, 505 N. Michigan Avenue, Chicago, IL 60611.

Contact Person: Steven J Zuillo, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5146, MSC 7849, Bethesda, MD 20892, 301–435–2810, zuillost@csr.nih.gov.


Dated: March 25, 2011.

Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–7644 Filed 3–30–11; 8:45 am]
BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Next Generation PrEP.

Date: April 29, 2011.

Time: 1:30 p.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).

Contact Person: Roberta Binder, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, NIAID/NIH/DHHS, 6700B Rockledge Drive, Room 3130, Bethesda, MD 20892–7616, 301–496–7966, rbinder@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: March 25, 2011.

Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–7644 Filed 3–30–11; 8:45 am]
BILLING CODE 4160–01–P